Literature DB >> 15819798

Liver transplantation with preservation of the inferior vena cava in case of symptomatic adult polycystic disease.

Jan Lerut1, Olga Ciccarelli, Matthieu Rutgers, Giuseppe Orlando, Jules Mathijs, Etienne Danse, Eric Goffin, Jean-François Gigot, Pierre Goffette.   

Abstract

Adult polycystic liver disease (APLD) is a rare disorder of the liver parenchyma, the treatment of which is still controversial. Conservative surgery may have a significant morbidity and is often ineffective in the long run. Liver replacement may be indicated in case of incapacitating hepatomegaly. Patients (one male, five females) undergoing liver transplantation for symptomatic APLD is presented in this study. The particular nature of this series is the fact that successful transplantation was performed in all cases with preservation of the recipient's inferior vena cava and without use of veno-venous bypass despite massive hepatomegaly and previous extensive liver surgery (in three cases). There was minimal morbidity and no mortality. All patients have excellent quality of life with a median follow-up of 41 months (range: 12-58) as testified by a median Karnofsky score of 90% (range: 80-100%).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15819798     DOI: 10.1111/j.1432-2277.2005.00061.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  2 in total

1.  Orthotopic liver transplantation for giant liver haemangioma: A case report.

Authors:  Undine G Lange; Julian N Bucher; Markus B Schoenberg; Christian Benzing; Moritz Schmelzle; Tanja Gradistanac; Steffen Strocka; Hans-Michael Hau; Michael Bartels
Journal:  World J Transplant       Date:  2015-12-24

Review 2.  Treatment of Polycystic Liver Disease: Impact on Patient-reported Symptom Severity and Health-related Quality of Life.

Authors:  Renée Duijzer; Thijs R M Barten; Christian B Staring; Joost P H Drenth; Tom J G Gevers
Journal:  J Clin Gastroenterol       Date:  2022-08-19       Impact factor: 3.174

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.